Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer
Platelets are small anucleate cells that are traditionally described as the major effectors of hemos...
Cancer-related venous thromboembolism (VTE) is frequent and constitutes the second leading cause of ...
Cancer is a common cause of morbidity and mortality in the USA. While the association between venous...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe primary hemostatic function of platelets has been recognized for more than...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
The first cause of death in cancer patients, after tumoral progression itself, is thrombo-embolic di...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
International audienceThe primary hemostatic function of platelets has been recognized for more than...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
The relationship between hemostasis and malignancy is well recognized, with both elements interactin...
Platelets are small anucleate cells that are traditionally described as the major effectors of hemos...
Platelets are small anucleate cells that are traditionally described as the major effectors of hemos...
Cancer-related venous thromboembolism (VTE) is frequent and constitutes the second leading cause of ...
Cancer is a common cause of morbidity and mortality in the USA. While the association between venous...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
International audienceThe primary hemostatic function of platelets has been recognized for more than...
International audienceThe first cause of death in cancer patients, after tumoral progression itself,...
The first cause of death in cancer patients, after tumoral progression itself, is thrombo-embolic di...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
International audienceThe primary hemostatic function of platelets has been recognized for more than...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
The relationship between hemostasis and malignancy is well recognized, with both elements interactin...
Platelets are small anucleate cells that are traditionally described as the major effectors of hemos...
Platelets are small anucleate cells that are traditionally described as the major effectors of hemos...
Cancer-related venous thromboembolism (VTE) is frequent and constitutes the second leading cause of ...
Cancer is a common cause of morbidity and mortality in the USA. While the association between venous...